ImmuPharma plc (LON:IMM – Get Free Report)’s stock price rose 13.9% during mid-day trading on Thursday . The company traded as high as GBX 3.98 and last traded at GBX 3.98. 1,159,174 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 2,466,091 shares. The stock had previously closed at GBX 3.50.
ImmuPharma Price Performance
The company has a 50 day simple moving average of GBX 3.87 and a 200-day simple moving average of GBX 4.47. The stock has a market capitalization of £24.83 million, a P/E ratio of -10.76 and a beta of 3.01.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.84) earnings per share for the quarter. ImmuPharma had a negative return on equity of 633.14% and a net margin of 3,519.56%. As a group, equities analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
- Apple Is Quietly Building an AI Advantage Few Expected
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
